Welcome to our dedicated page for 22Nd Century SEC filings (Ticker: XXII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a plant-biotech tobacco company navigates the SEC can feel like decoding a laboratory notebook. 22nd Century Group’s filings blend patent disclosures on genetically engineered nicotine plants, FDA correspondence on its VLN® cigarette, and capacity updates from its Mocksville facility—details that sprawl across a 10-K well over 300 pages. If you have ever searched �22nd Century Group SEC filings explained simply� or needed �22nd Century Group 8-K material events explained,� you know the challenge: crucial datapoints hide behind dense regulatory language.
Stock Titan solves that problem. Our AI dissects every 22nd Century Group quarterly earnings report 10-Q filing, highlights unit sales for reduced-nicotine cigarettes, and flags R&D spending in seconds. Interactive dashboards turn the annual report into �22nd Century Group annual report 10-K simplified,� while sentence-level summaries offer �22nd Century Group earnings report filing analysis� you can skim during a coffee break. By understanding 22nd Century Group SEC documents with AI, investors quickly spot FDA milestones, cash burn trends, or new contract-manufacturing revenue without scrolling through footnotes.
Need to monitor executive incentives or potential signals from insiders? Receive instant alerts on �22nd Century Group insider trading Form 4 transactions� and review �22nd Century Group Form 4 insider transactions real-time.� Our coverage links each trade to the appropriate �22nd Century Group executive stock transactions Form 4� so you can correlate buying or selling with fresh disclosures. Proxy tools clarify �22nd Century Group proxy statement executive compensation,� and real-time feeds ensure no filing�10-K, 10-Q, 8-K, or S-3—escapes your radar. Complex biotech-tobacco filings, delivered in plain English and updated the moment EDGAR releases them.
UBS AG is offering Contingent Income Auto-Callable Securities linked to the common stock of PayPal Holdings, Inc. (PYPL). The notes are senior unsecured obligations of UBS AG London Branch, priced at $1,000 per security, with expected issuance on 16 July 2025 and maturity on or about 14 July 2028 (�36 months).
Coupon mechanics: investors receive a fixed contingent payment of $27.875 per quarter (�11.15 % p.a.) for any determination date on which PYPL’s closing price is at least 65 % of the initial price (“downside threshold�). If, on any determination date other than the final one, PYPL closes at or above 100 % of the initial price (“call threshold�), the notes are automatically redeemed for $1,000 + the current coupon.
Principal repayment: � If the final price on 11 July 2028 is �65 % of the initial price, holders receive principal plus the final coupon. � If it is <65 %, UBS will pay a cash value equal to the percentage decline in PYPL, exposing investors to a 1-for-1 loss below the threshold and up to 100 % loss of principal. There is no upside participation in PYPL shares.
Key economics & costs: � Estimated initial value: $937.30 � $967.30 (3.3 %-6.3 % below issue price), reflecting dealer margins, hedging and funding costs. � Up-front fees total 2.25 % of principal (1.75 % sales commission, 0.50 % structuring fee). � Securities will not be listed; UBS Securities LLC intends, but is not obligated, to provide a secondary market.
Risk highlights: investors face (i) issuer credit risk of UBS AG, (ii) equity risk in PYPL, (iii) liquidity risk given the unlisted nature, (iv) early-call reinvestment risk, and (v) tax uncertainty; the notes are treated as prepaid derivatives with ordinary-income coupons.
Investor profile: suitable only for sophisticated investors who can tolerate loss of principal, limited upside, and illiquidity in exchange for above-market contingent income.
22nd Century Group (XXII) has entered into a significant Master Services Agreement with an existing customer, expanding their manufacturing partnership. The new five-year exclusive agreement represents a substantial expansion of their previous supply relationship.
Key aspects of the agreement include:
- Exclusive manufacturing rights for four existing Pinnacle cigarette brands currently in retail distribution
- Rights to manufacture up to seven new products, including three low nicotine SKUs, two natural style brands, and two moist snuff products
- Royalty payment structure to Customer for each carton manufactured and sold to distributors
This strategic agreement strengthens 22nd Century Group's position in the tobacco manufacturing sector and expands their product portfolio beyond their previous cigarette-only supply arrangement. The agreement's details will be fully disclosed in the company's upcoming Annual Report.
22nd Century Group, Inc. (Nasdaq: XXII) has filed a Form S-3 shelf registration statement covering the potential resale of up to 8,588,811 shares of common stock. The shares are issuable upon exercise of warrants that were granted in two recent private placements (October 24 2024 and April 30 2025). The warrants include an “alternate cashless exercise� feature that allows holders to receive two shares for a zero exercise price, meaning the company will not receive any cash proceeds when the warrants are exercised. 22nd Century will also receive no proceeds from subsequent sales by the selling stockholders; it is registering the shares solely to permit their resale.
The company classifies itself as a non-accelerated filer and a smaller reporting company. The filing indicates that the shares may be sold from time to time in a variety of transactions—at fixed, market, or negotiated prices—without underwriting discounts paid by the company. 22nd Century has agreed to bear the registration expenses, while the selling stockholders will cover any brokerage commissions.
Key reference data contained in the filing include: (i) 4,851,913 shares tied to October 2024 investor warrants, (ii) 300,458 shares related to placement-agent warrants from the same 2024 transaction, and (iii) 3,436,440 shares issuable from April 2025 warrants. The company’s common stock last closed at $10.12 on 18 June 2025. Investors are directed to the prospectus Risk Factors section—which highlights continued operating losses, Nasdaq compliance concerns, and competitive pressures—for a full discussion of potential hazards.
Implications for shareholders:
- The registration increases the tradable float by up to 8.6 million shares, potentially creating share-price overhang.
- Because the cashless exercise delivers shares without payment, the transaction is non-dilutive to cash but dilutive to EPS and ownership percentages.
- No capital inflow means the company’s liquidity position is unchanged by this filing.
FAQ
What is the current stock price of 22Nd Century (XXII)?
What is the market cap of 22Nd Century (XXII)?
What is the primary mission of 22nd Century Group Inc.?
How does 22nd Century achieve nicotine reduction in its products?
What distinguishes 22nd Century's VLN cigarettes in the market?
What are the key revenue streams for 22nd Century?
How does the company ensure product quality and scalability?
What role do the subsidiaries play in the overall business model?
Does the company have any involvement in cannabis technology?
How does 22nd Century manage its research and development initiatives?
